Skip to main content
. 2021 Jan 21;28(2):626–639. doi: 10.1038/s41418-020-00720-9

Fig. 5. Twelve candidate vaccines currently in Phase III trial. COVID-19 Vaccines based on Spike protein DNA carried by adenoviruses.

Fig. 5

The Chinese Can Sino Ad5-nCoV and the Russian Gamaley Res. Inst. Sputnik V vaccines have already obtained a limited authorization and have been administered to sections of the population. Despite the excellent preliminary results and well-documented immunogenicity, the Phase III trial on AstraZeneca/University of Oxford ChAdOx1 vaccine provided provocative but somewhat contradictory results that require further study [8].